Abdeljaoued Syrine, Bettaieb Lhem, Nasri Meher, Adouni Olfa, Goucha Aida, Bouzaiene Hatem, Boussen Hamouda, Rahal Khaled, Gamoudi Amor
Department of Immuno-Histo-Cytology, Salah Azaïz Cancer Institute, Bab Saadoun, 1006 Tunis, Tunisia.
Department of Medical Oncology, Salah Azaïz Cancer Institute, Bab Saadoun, 1006 Tunis, Tunisia.
Breast Dis. 2018;37(3):109-114. doi: 10.3233/BD-170315.
Male breast cancer (MBC) is a rare and neglected disease. Prognostic and predictive factors in MBC are extrapoled from trials conducted on its female counterpart.
Since the relationship between the transcription factor Forkhead box M1 (FOXM1) expression and the clinical response to chemotherapy and hormonotherapy in MBC remains unknown, we sought to investigate the predictive value of FOXM1 in MBC.
FOXM1 expression was assessed in 130 MBC cases. Clinical significance was analyzed by Kaplan Meier curves, log-rank test and multivariate Cox regression analyses.
Patients with high FOXM1 expression had a significantly lower response rate to chemotherapy (P = 0.045) and hormonotherapy (P = 0.029) than those with low FOXM1 expression. Multivariate analyses indicated that FOXM1 was an independent prognostic factor for disease free survival in MBC patients (P < 0.001).
FOXM1 may have a reliable predictive significance in male breast cancer and thus may become an important target for male breast cancer therapy in the near future.
男性乳腺癌（MBC）是一种罕见且被忽视的疾病。MBC的预后和预测因素是从针对女性乳腺癌进行的试验中推断出来的。
由于转录因子叉头框M1（FOXM1）表达与MBC化疗及激素治疗临床反应之间的关系尚不清楚，我们试图研究FOXM1在MBC中的预测价值。
对130例MBC病例评估FOXM1表达。通过Kaplan-Meier曲线、对数秩检验和多变量Cox回归分析来分析临床意义。
与低FOXM1表达的患者相比，高FOXM1表达的患者对化疗（P = 0.045）和激素治疗（P = 0.029）的反应率显著更低。多变量分析表明，FOXM1是MBC患者无病生存的独立预后因素（P < 0.001）。
FOXM1可能在男性乳腺癌中具有可靠的预测意义，因此在不久的将来可能成为男性乳腺癌治疗的重要靶点。
